Suchergebnisse - "Bone Density Conservation Agents administration & dosage"

Traitements médicamenteux séquentiels de l’ostéoporose

Autoren: Lamy, Olivier Meier, Christian Everts-Graber, Judith et al.

Quelle: Revue Médicale Suisse. 21:783-787

Schlagwörter: Antibodies, Monoclonal, Diphosphonates / administration & dosage, Drug Administration Schedule, Osteoporosis / complications, Osteoporosis / drug therapy, Denosumab / therapeutic use, Denosumab / administration & dosage, Diphosphonates / therapeutic use, Bone Density Conservation Agents / therapeutic use, Humans, Teriparatide / administration & dosage, Bone Density Conservation Agents / administration & dosage, Osteoporotic Fractures / prevention & control

Dateibeschreibung: application/pdf

Zugangs-URL: https://archive-ouverte.unige.ch/unige:184695
https://doi.org/10.53738/revmed.2025.21.914.47112

Denosumab for osteoporosis treatment: when, how, for whom, and for how long. A pragmatical approach

Autoren: Olivier Lamy Judith Everts-Graber Elena Gonzalez Rodriguez

Quelle: Aging Clin Exp Res
Aging clinical and experimental research, vol. 37, no. 1, pp. 70

Schlagwörter: Humans, Denosumab/therapeutic use, Denosumab/adverse effects, Denosumab/administration & dosage, Bone Density Conservation Agents/therapeutic use, Bone Density Conservation Agents/adverse effects, Bone Density Conservation Agents/administration & dosage, Osteoporosis/drug therapy, Female, Bone Density/drug effects, Diphosphonates/therapeutic use, Denosumab, Fracture, Multiple vertebral fractures, Osteoporosis, Rebound effect, Bone Density Conservation Agents, Diphosphonates, Bone Density, Review

Dateibeschreibung: application/pdf

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/40055268
https://serval.unil.ch/notice/serval:BIB_E4C8D530B910
http://nbn-resolving.org/urn/resolver.pl?urn=urn:nbn:ch:serval-BIB_E4C8D530B9107
https://serval.unil.ch/resource/serval:BIB_E4C8D530B910.P001/REF.pdf

Traitements médicamenteux séquentiels de l’ostéoporose [Sequential drug treatments for osteoporosis]

Autoren: Lamy, O. Meier, C. Everts-Graber, J. et al.

Quelle: Revue medicale suisse, vol. 21, no. 914, pp. 783-787

Schlagwörter: Humans, Osteoporosis/drug therapy, Osteoporosis/complications, Bone Density Conservation Agents/administration & dosage, Bone Density Conservation Agents/therapeutic use, Denosumab/administration & dosage, Denosumab/therapeutic use, Diphosphonates/administration & dosage, Diphosphonates/therapeutic use, Osteoporotic Fractures/prevention & control, Teriparatide/administration & dosage, Drug Administration Schedule, Antibodies, Monoclonal

Dateibeschreibung: application/pdf

Zugangs-URL: https://serval.unil.ch/resource/serval:BIB_4E78F1166BD1.P001/REF.pdf
https://serval.unil.ch/notice/serval:BIB_4E78F1166BD1
http://nbn-resolving.org/urn/resolver.pl?urn=urn:nbn:ch:serval-BIB_4E78F1166BD12

What impact do systemically administrated bisphosphonates have on oral implant therapy? A systematic review.

Autoren: Madrid, C. Sanz, M.

Schlagwörter: Administration, Oral, Animals, Bone Density Conservation Agents/administration & dosage, Bone Density Conservation Agents/adverse effects, Dental Care for Chronically Ill, Dental Implantation, Endosseous, Dental Implants, Dental Restoration Failure, Diphosphonates/administration & dosage, Diphosphonates/adverse effects, Humans, Injections, Intravenous, Jaw Diseases/chemically induced, Osseointegration/drug effects, Osteonecrosis/chemically induced, Practice Guidelines as Topic, Risk

Relation: Clinical Oral Implants Research; 1600-0501[electronic]; https://iris.unil.ch/handle/iris/234778; serval:BIB_E3D85F546D1D; 000268296200009

Verfügbarkeit: https://iris.unil.ch/handle/iris/234778
https://doi.org/10.1111/j.1600-0501.2009.01772.x

Fracture risk following intermission of osteoporosis therapy

Autoren: Cyrus Cooper Eugene V. McCloskey Olivier Bruyère et al.

Quelle: Dennison, E M, Cooper, C, Kanis, J A, Bruyère, O, Silverman, S, McCloskey, E, Abrahamsen, B, Prieto-Alhambra, D, Ferrari, S & On behalf of the IOF Epidemiology/Quality of Life Working Group 2019, ' Fracture risk following intermission of osteoporosis therapy ', Osteoporosis International, vol. 30, no. 9, pp. 1733-1743 . https://doi.org/10.1007/s00198-019-05002-w

Schlagwörter: drug holiday, Clinical Decision-Making/methods, Public health, health care sciences & services, Clinical Decision-Making, Sciences de la santé humaine, Risk Assessment, Santé publique, services médicaux & soins de santé, Drug Administration Schedule, 03 medical and health sciences, 0302 clinical medicine, Rheumatology, Bone Density, Risk Factors, atypical fracture, Humans, Bone Density Conservation Agents/administration & dosage, Gériatrie, Postmenopausal/drug therapy, Drug holiday, Denosumab/administration & dosage, Human health sciences, Risk Assessment/methods, bisphosphonates, Bisphosphonate-Associated Osteonecrosis of the Jaw/epidemiology, Osteoporosis, Postmenopausal, Bone Density Conservation Agents, Diphosphonates, Age Factors, denosumab, Bisphosphonates, Osteoporotic Fractures/epidemiology, 3. Good health, Diphosphonates/administration & dosage, Rhumatologie, Withholding Treatment, Geriatrics, Osteoporosis, Bisphosphonate-Associated Osteonecrosis of the Jaw, Bone Density/physiology, Denosumab, Atypical fracture, Osteoporotic Fractures

Dateibeschreibung: application/pdf; text

Zugangs-URL: https://eprints.soton.ac.uk/429724/1/IOF_WG_Interruption_accepted_March_2019.docx
https://pubmed.ncbi.nlm.nih.gov/31175404
https://researchbank.acu.edu.au/cgi/viewcontent.cgi?article=12318&context=fhs_pub
https://link.springer.com/article/10.1007/s00198-019-05002-w
https://www.ndorms.ox.ac.uk/publications/986782
https://jglobal.jst.go.jp/en/detail?JGLOBAL_ID=201902265591626689
https://archive-ouverte.unige.ch/unige:134040
https://acuresearchbank.acu.edu.au/item/86z76/fracture-risk-following-intermission-of-osteoporosis-therapy
https://ora.ox.ac.uk/objects/uuid:cd690930-08f5-4c3b-8411-419b638331d9
https://doi.org/10.1007/s00198-019-05002-w
https://archive-ouverte.unige.ch/unige:134040
https://doi.org/10.1007/s00198-019-05002-w
https://findresearcher.sdu.dk:8443/ws/files/170258735/IOF_WG_Interruption_accepted_March_2019_1_.pdf
https://portal.findresearcher.sdu.dk/da/publications/a096eeb2-b735-4217-b419-e8709e97a8fc
https://doi.org/10.1007/s00198-019-05002-w
https://acuresearchbank.acu.edu.au/item/86z76/fracture-risk-following-intermission-of-osteoporosis-therapy
https://eprints.soton.ac.uk/429724/

Use of antiosteoporotic medication in the Danish ROSE population-based screening study

Autoren: Anne Pernille Hermann Mikkel Høiberg Katrine Hass Rubin et al.

Quelle: Høiberg, M P, Rubin, K H, Holmberg, T, Rothmann, M J, Möller, S, Gram, J, Bech, M, Brixen, K & Hermann, A P 2019, ' Use of antiosteoporotic medication in the Danish ROSE population-based screening study ', Osteoporosis International, vol. 30, no. 6, pp. 1223-1233 . https://doi.org/10.1007/s00198-019-04934-7

Schlagwörter: Treatment Refusal/statistics & numerical data, Denmark, Photon/methods, Osteoporotic Fractures/etiology, Medication, Risk Assessment, Persistence, Treatment Refusal, 03 medical and health sciences, Absorptiometry, Photon, 0302 clinical medicine, Mass Screening/methods, Population-based screening, 80 and over, Humans, Mass Screening, Bone Density Conservation Agents/administration & dosage, Registries, Absorptiometry, Risk Assessment/methods, Osteoporosis, Postmenopausal, Aged, Aged, 80 and over, Assessment of Medication Adherence, Bone Density Conservation Agents, Drug Utilization/statistics & numerical data, Postmenopausal/complications, Middle Aged, 16. Peace & justice, Drug Utilization, 3. Good health, Adherence, Medication Adherence/statistics & numerical data, Osteoporosis, Female, Osteoporotic Fractures, Compliance

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/30911782
https://www.ncbi.nlm.nih.gov/pubmed/30911782
http://www.ncbi.nlm.nih.gov/pubmed/30911782
https://link.springer.com/article/10.1007/s00198-019-04934-7
https://europepmc.org/article/MED/30911782
https://portal.findresearcher.sdu.dk/da/publications/use-of-antiosteoporotic-medication-in-the-danish-rose-population-
https://portal.findresearcher.sdu.dk/da/publications/1cc3db0a-588e-4199-b758-b0d851a63616

Surgically treated osteonecrosis and osteomyelitis of the jaw and oral cavity in patients highly adherent to alendronate treatment: a nationwide user-only cohort study including over 60,000 alendronate users: a nationwide user-only cohort study including over 60,000 alendronate users

Autoren: Eiken, P A Prieto-Alhambra, D Eastell, R et al.

Quelle: Eiken, P A, Prieto-Alhambra, D, Eastell, R & Abrahamsen, B 2017, ' Surgically treated osteonecrosis and osteomyelitis of the jaw and oral cavity in patients highly adherent to alendronate treatment : a nationwide user-only cohort study including over 60,000 alendronate users ', Osteoporosis International, vol. 28, no. 10, pp. 2921–2928 . https://doi.org/10.1007/s00198-017-4132-y

Schlagwörter: Oral, Male, Epidemiology, Denmark, Administration, Oral, Comorbidity, Drug Administration Schedule, Cohort Studies, 03 medical and health sciences, 0302 clinical medicine, Risk Factors, Journal Article, 80 and over, Humans, Bone Density Conservation Agents/administration & dosage, Registries, Osteomyelitis/chemically induced, Bisphosphonate-Associated Osteonecrosis of the Jaw/epidemiology, Aged, Aged, 80 and over, Biphosphonates, Osteonecrosis of the jaw, Alendronate, Bone Density Conservation Agents, Osteomyelitis, Middle Aged, Denmark/epidemiology, 3. Good health, Osteomyelitis of the jaw, Risk factors, Alendronate/administration & dosage, Case-Control Studies, Administration, Osteoporosis, Surgery, Bisphosphonate-Associated Osteonecrosis of the Jaw, Female, Osteoporosis/drug therapy

Zugangs-URL: https://ora.ox.ac.uk/objects/uuid:176954b8-8cce-42a0-9266-43e652b2c7aa/download_file?safe_filename=Prieto%2Bet%2Bal%252C%2BSurgically%2Btreated%2Bosteonecrosis%2Band%2Bosteomyelitis%2Bof%2Bthe%2Bjaw%2Band%2Boral%2Bcavity%2Bin%2Bpatients%2Bhighly%2Badherent%2Bto.pdf&file_format=application%2Fpdf&type_of_work=Journal+article
https://pubmed.ncbi.nlm.nih.gov/28664276
https://pubmed.ncbi.nlm.nih.gov/28664276/
https://europepmc.org/article/MED/28664276
https://rd.springer.com/article/10.1007%2Fs00198-017-4132-y
https://www.ndorms.ox.ac.uk/publications/708123
https://www.ncbi.nlm.nih.gov/pubmed/28664276
https://core.ac.uk/display/84337299
https://portal.findresearcher.sdu.dk/da/publications/6db3ac39-83b1-445d-bdac-7a938c6da583

International Osteoporosis Foundation and European Calcified Tissue Society Working Group. Recommendations for the screening of adherence to oral bisphosphonates

Autoren: Diez-Perez, A Naylor, KE Abrahamsen, B et al.

Quelle: Osteoporosis International, Vol. 28, No 3 (2017) pp. 767-774
Diez-Perez, A, Naylor, K E, Abrahamsen, B, Agnusdei, D, Brandi, M L, Cooper, C, Dennison, EM, Eriksen, E F, Gold, D T, Guañabens, N, Hadji, P, Hiligsmann, M, Horne, R, Josse, R, Kanis, J A, Obermayer-Pietsch, B, Prieto-Alhambra, D, Reginster, J-Y, Rizzoli, R, Silverman, S, Zillikens, M C & Eastell, R 2017, ' International Osteoporosis Foundation and European Calcified Tissue Society Working Group. Recommendations for the screening of adherence to oral bisphosphonates ', Osteoporosis International, vol. 28, no. 3, pp. 767-774 . https://doi.org/10.1007/s00198-017-3906-6

Schlagwörter: Procollagen/blood, Peptides/blood, Osteoporosis treatment, Drug Evaluation, Preclinical, Administration, Oral, POSTMENOPAUSAL OSTEOPOROSIS, THERAPY, 0302 clinical medicine, Position paper, Human health sciences, AUTOMATED SERUM ASSAY, Adherence, Bisphosphonates, Screening, Osteoporosis, Postmenopausal, ddc:616, RISK, treatment, Bone Density Conservation Agents, Diphosphonates, WOMEN, 3. Good health, Diphosphonates/administration & dosage, Bone Remodeling/physiology, Administration, Female, Bone Remodeling, Médecine générale & interne, Procollagen, Oral, BONE TURNOVER MARKERS, Collagen Type I/blood, EMC OR-01, I COLLAGEN, Sciences de la santé humaine, Collagen Type I, Medication Adherence, 03 medical and health sciences, Humans, Bone Density Conservation Agents/administration & dosage, Postmenopausal/drug therapy, BIOCHEMICAL MARKERS, PERSISTENCE, HISTOMORPHOMETRY, Peptide Fragments, Preclinical/methods, Osteoporosis, Drug Evaluation, General & internal medicine, Peptide Fragments/blood, Peptides, Biomarkers/blood, Biomarkers

Dateibeschreibung: application/pdf; text

Zugangs-URL: https://europepmc.org/articles/pmc5302161?pdf=render
https://pubmed.ncbi.nlm.nih.gov/28093634
https://pure.eur.nl/en/publications/0f1d53af-b016-414f-950a-afe1d959f37a
https://doi.org/10.1007/s00198-017-3906-6
https://cris.maastrichtuniversity.nl/en/publications/6b17bfec-fbe1-4d54-8bf3-c3bea9274ee3
https://doi.org/10.1007/s00198-017-3906-6
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5302161/
https://archive-ouverte.unige.ch/unige:93313
https://europepmc.org/articles/PMC5302161
https://flore.unifi.it/handle/2158/1074087
https://www.ndorms.ox.ac.uk/publications/671659
https://core.ac.uk/display/154997190
https://ora.ox.ac.uk/objects/uuid:b7423010-6c80-4937-bebb-8ea353a0e3a1
https://doi.org/10.1007/s00198-017-3906-6
https://hdl.handle.net/2268/212766
https://doi.org/10.1007/s00198-017-3906-6
https://archive-ouverte.unige.ch/unige:93313
https://archive-ouverte.unige.ch/unige:93313
https://doi.org/10.1007/s00198-017-3906-6
https://findresearcher.sdu.dk:8443/ws/files/135455496/International_Osteoporosis_Foundation_and_European_Calcified_Tissue_Society_Working_Group._Recommendations_for_the_screening_of_adherence_to_oral_bisphosphonates.pdf
https://portal.findresearcher.sdu.dk/da/publications/00e99cf2-9b20-4e33-a718-8f1b2fcec41f
https://doi.org/10.1007/s00198-017-3906-6
https://acuresearchbank.acu.edu.au/item/8942w/international-osteoporosis-foundation-and-european-calcified-tissue-society-working-group-recommendations-for-the-screening-of-adherence-to-oral-bisphosphonates
https://hdl.handle.net/2158/1074087
http://link.springer.com/article/10.1007/s00198-017-3906-6
https://doi.org/10.1007/s00198-017-3906-6
https://discovery-pp.ucl.ac.uk/id/eprint/1547595/
https://eprints.soton.ac.uk/404568/

Osteoporosebehandling kan pauseres efter individuel vurdering

Autoren: Eiken, Pia Agnete Abrahamsen, Bo

Quelle: Eiken, P A & Abrahamsen, B 2017, ' Osteoporosebehandling kan pauseres efter individuel vurdering ', Ugeskrift for Laeger, bind 179, nr. 4, V05160327, s. 335-342 .

Schlagwörter: Bone Density/drug effects, Teriparatide/administration & dosage, Middle Aged, Biomarkers/analysis, 3. Good health, Diphosphonates/administration & dosage, Withholding Treatment, Bone Remodeling/drug effects, Humans, Bone Density Conservation Agents/administration & dosage, Thiophenes/administration & dosage, Denosumab/administration & dosage, Precision Medicine, Aged, Osteoporosis/drug therapy

Zugangs-URL: https://portal.findresearcher.sdu.dk/da/publications/a470cf80-68fa-401f-b132-1d91d12c467e

Multiple vertebral fractures after denosumab discontinuation / Multiple vertebrale frakturer efter ophör med denosumab

Autoren: Tjelum, Louise Eiken, Pia

Quelle: Ugeskrift for Laeger. 181(18):1711

The effect of bisphosphonate treatment on osteoclast precursor cells in postmenopausal osteoporosis: The TRIO study: The TRIO study

Autoren: Gossiel, F. Hoyle, C. McCloskey, E.V. et al.

Quelle: Gossiel, F, Hoyle, C, McCloskey, E V, Naylor, K E, Walsh, J, Peel, N & Eastell, R 2016, 'The effect of bisphosphonate treatment on osteoclast precursor cells in postmenopausal osteoporosis : The TRIO study', Bone, vol. 92, pp. 94-99. https://doi.org/10.1016/j.bone.2016.08.010

Schlagwörter: Oral, Adult, 0301 basic medicine, Postmenopausal/blood, Administration, Oral, Osteoclasts, 03 medical and health sciences, Humans, Bone Density Conservation Agents/administration & dosage, Osteoporosis, Postmenopausal, Aged, Peripheral Blood Stem Cells/drug effects, 0303 health sciences, Bone Density Conservation Agents, Diphosphonates, 4. Education, Osteoporosis, Postmenopausal/blood, Middle Aged, Flow Cytometry, Flow Cytometry/methods, 3. Good health, Diphosphonates/administration & dosage, Treatment Outcome, Administration, Bone Remodeling/drug effects, Peripheral Blood Stem Cells, Osteoporosis, Osteoclasts/drug effects, Female, Bone Remodeling

Dateibeschreibung: application/pdf

Zugangs-URL: http://eprints.whiterose.ac.uk/106976/3/Gossiel%20et%20al%202016%20BONE.pdf
https://pubmed.ncbi.nlm.nih.gov/27535783
https://core.ac.uk/display/59922615
https://pubmed.ncbi.nlm.nih.gov/27535783/
https://www.ncbi.nlm.nih.gov/pubmed/27535783
https://www.sciencedirect.com/science/article/pii/S8756328216302290
https://eprints.whiterose.ac.uk/106976/
https://www.research.manchester.ac.uk/portal/en/publications/the-effect-of-bisphosphonate-treatment-on-osteoclast-precursor-cells-in-postmenopausal-osteoporosis(d70d4f15-8d9b-4258-9082-40fa3f7aaaaf).html

Traitement par bisphosphonates et bilan dentaire préalable [Treatment with bisphosphonates and previous dental health]

Autoren: Madrid, C. Bouferrache, K. Jaques, B. et al.

Schlagwörter: Bone Density Conservation Agents/administration & dosage, Bone Density Conservation Agents/adverse effects, DMF Index, Diphosphonates/administration & dosage, Diphosphonates/adverse effects, Evidence-Based Medicine, Humans, Jaw Diseases/chemically induced, Oral Health, Osteonecrosis/chemically induced, Osteoporosis/drug therapy

Relation: Revue médicale suisse; https://iris.unil.ch/handle/iris/260289; serval:BIB_F6627F7DEDE5

Verfügbarkeit: https://iris.unil.ch/handle/iris/260289

Comment gérer l'effet rebond à l'arrêt du dénosumab et éviter les fractures vertébrales multiples?

Autoren: Gonzalez Rodriguez, Elena Lamy, Olivier Aubry-Rozier, Bérengère et al.

Quelle: ISSN: 1660-9379 ; Revue médicale suisse, vol. 15, no. 647 (2019) p. 831-835.

Schlagwörter: info:eu-repo/classification/ddc/616, Bone Density Conservation Agents/administration & dosage/adverse effects, Bone Remodeling, Denosumab/administration & dosage/adverse effects, Diphosphonates, Humans, Osteoporosis, Postmenopausal/drug therapy, Spinal Fractures/chemically induced/prevention & control

Relation: info:eu-repo/semantics/altIdentifier/pmid/30994986; unige:123833

Verfügbarkeit: https://archive-ouverte.unige.ch/unige:123833

Interventions for preventing falls in people after stroke

Autoren: Denissen, Stijn Staring, Wouter Kunkel, Dorit et al.

Quelle: ISSN:1469-493X ; ISSN:1361-6137 ; Cochrane Database Of Systematic Reviews, vol. 10 (10), Art.No. CD008728.

Schlagwörter: Science & Technology, Life Sciences & Biomedicine, Medicine, General & Internal, General & Internal Medicine, Accidental Falls [*prevention & control] [statistics& numerical data], Alendronate [administration & dosage], Bone Density Conservation Agents [administration & dosage], Exercise, Eyeglasses, Randomized Controlled Trials as Topic, Stroke [*complications], Vitamin D [administration & dosage], Vitamins [administration & dosage], Female, Humans, Male, RANDOMIZED CONTROLLED-TRIAL, COMMUNITY-DWELLING PEOPLE, EARLY REHABILITATION TRIAL, EARLY SUPPORTED DISCHARGE, ANKLE-FOOT ORTHOSIS, QUALITY-OF-LIFE, PHASE-II, TAI CHI, EXERCISE PROGRAM, MEDICAL COMPLICATIONS, 11 Medical and Health Sciences, 17 Psychology and Cognitive Sciences, 32 Biomedical and clinical sciences

Dateibeschreibung: application/pdf; text/html

Relation: https://lirias.kuleuven.be/handle/123456789/643794; https://doi.org/10.1002/14651858.CD008728.pub3.; https://pubmed.ncbi.nlm.nih.gov/31573069

Verfügbarkeit: https://lirias.kuleuven.be/handle/123456789/643794
https://lirias.kuleuven.be/retrieve/fba7eca7-9768-4713-acff-41f744b4971e
https://lirias.kuleuven.be/retrieve/6446e5d1-c224-40e2-9b25-c5059715ee8c
https://doi.org/10.1002/14651858.CD008728.pub3
https://pubmed.ncbi.nlm.nih.gov/31573069

Anti-osteoporotic therapy in Denmark—predictors and demographics of poor refill compliance and poor persistence

Autoren: Hansen, Carrinna Pedersen, Birthe D. Konradsen, Hanne et al.

Quelle: Hansen, C, Pedersen, B D, Konradsen, H & Abrahamsen, B 2013, ' Anti-osteoporotic therapy in Denmark-predictors and demographics of poor refill compliance and poor persistence ', Osteoporosis International, vol. 24, no. 7, pp. 2079-2097 . https://doi.org/10.1007/s00198-012-2221-5

Schlagwörter: Oral, Adult, Male, Denmark, Administration, Oral, Comorbidity, Kaplan-Meier Estimate, Cohort Studies, 03 medical and health sciences, 0302 clinical medicine, Risk Factors, 80 and over, Humans, Bone Density Conservation Agents/administration & dosage, Administration, Oral Adult Aged Aged, 80 and over Bone Density Conservation Agents/administration & dosage/*therapeutic use Cohort Studies Comorbidity Denmark/epidemiology Diphosphonates/administration & dosage/*therapeutic use Female Humans Kaplan-Meier Estimate Male Medication Adherence/*statistics & numerical data Middle Aged Osteoporosis/*drug therapy/epidemiology Osteoporotic Fractures/prevention & control Polypharmacy Risk Factors Socioeconomic Factors, Aged, Aged, 80 and over, Assessment of Medication Adherence, Osteoporotic Fractures/prevention & control, Bone Density Conservation Agents, Diphosphonates, Middle Aged, Denmark/epidemiology, 3. Good health, Diphosphonates/administration & dosage, 80 and over Bone Density Conservation Agents/administration & dosage/*therapeutic use Cohort Studies Comorbidity Denmark/epidemiology Diphosphonates/administration & dosage/*therapeutic use Female Humans Kaplan-Meier Estimate Male Medication Adherence/*statistics & numerical data Middle Aged Osteoporosis/*drug therapy/epidemiology Osteoporotic Fractures/prevention & control Polypharmacy Risk Factors Socioeconomic Factors, Socioeconomic Factors, Administration, Medication Adherence/statistics & numerical data, Polypharmacy, Oral Adult Aged Aged, Osteoporosis, Female, Osteoporotic Fractures, Osteoporosis/drug therapy

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/23179576
http://www.ncbi.nlm.nih.gov/pubmed/23179576/
https://pubmed.ncbi.nlm.nih.gov/23179576/
https://link.springer.com/article/10.1007/s00198-012-2221-5
https://research.regionh.dk/files/36547334/PUBLISHED_Anti_osteoporotic_therapy_in_Denmark.pdf
https://portal.findresearcher.sdu.dk/da/publications/ab681675-e4dd-4827-aa85-bbfab3410382

Risk of cardiac valvulopathy with use of bisphosphonates: a population-based, multi-country case-control study

Autoren: Coloma, P. M. de Ridder, M. Bezemer, I. et al.

Weitere Verfasser: Coloma, P. M. de Ridder, M. Bezemer, I. et al.

Quelle: Osteoporos Int
Coloma, P M, de Ridder, M, Bezemer, I, Herings, R M, Gini, R, Pecchioli, S, Scotti, L, Rijnbeek, P, Mosseveld, M, van der Lei, J, Trifiro, G, Sturkenboom, M & Consortium, E-A 2016, 'Risk of cardiac valvulopathy with use of bisphosphonates: a population-based, multi-country case-control study', Osteoporosis International, vol. 27, no. 5, pp. 1857-1867. https://doi.org/10.1007/s00198-015-3441-2

Schlagwörter: Male, Databases, Factual, Bisphosphonates, Cardiac valve disorders, Cardiac valve regurgitation, Drug-induced valvular heart disease, Drug-induced valvulopathy, Endocrinology, Diabetes and Metabolism, 80 and over Bone Density Conservation Agents/administration & dosage/*adverse effects Case-Control Studies Databases, EMC NIHES-03-77-02, Heart Valve Diseases, Risk Assessment, Sensitivity and Specificity, Drug Administration Schedule, 03 medical and health sciences, Endocrinology, 0302 clinical medicine, Cardiac valve disorder, Bisphosphonate, Humans, Aged Aged, Aged, Netherlands, Aged, 80 and over, Bone Density Conservation Agents, Diphosphonates, Drug Substitution, Middle Aged, United Kingdom, 3. Good health, Diabetes and Metabolism, Italy, Factual Diphosphonates/administration & dosage/*adverse effects Drug Administration Schedule Drug Substitution Female Heart Valve Diseases/*chemically induced/epidemiology Humans Italy/epidemiology Male Middle Aged Netherlands/epidemiology Osteoporosis/drug therapy/epidemiology Risk Assessment/methods Sensitivity and Specificity United Kingdom/epidemiology Bisphosphonates Cardiac valve disorders Cardiac valve regurgitation Drug-induced valvular heart disease Drug-induced valvulopathy, Case-Control Studies, Osteoporosis, Original Article, Female

Dateibeschreibung: application/pdf

Zugangs-URL: https://link.springer.com/content/pdf/10.1007%2Fs00198-015-3441-2.pdf
https://pubmed.ncbi.nlm.nih.gov/26694594
https://pure.eur.nl/en/publications/aab3e778-5a35-46e1-beb3-7abf4ef7ac5c
https://doi.org/10.1007/s00198-015-3441-2
https://research.vumc.nl/en/publications/25fe7370-7562-4377-ac85-03d34c02cbb8
https://hdl.handle.net/11562/1039560
https://doi.org/10.1007/s00198-015-3441-2

Treatment breaks in long-term management of osteoporosis:Treatment breaks in long-term management of osteoporosis

Autoren: Langdahl, Bente

Quelle: Langdahl, B 2019, 'Treatment breaks in long-term management of osteoporosis : Treatment breaks in long-term management of osteoporosis', European Journal of Endocrinology. Supplement, vol. 180, no. 1, pp. R29-R35. https://doi.org/10.1530/EJE-18-0282

Schlagwörter: Diphosphonates/administration & dosage, Disease Management, Humans, Bone Density Conservation Agents/administration & dosage, Drug Administration Schedule, 3. Good health, Osteoporosis/drug therapy

Zugangs-URL: https://pure.au.dk/portal/en/publications/7bfeb577-a2ac-49bf-8a51-8f8da1968f48

Polycaprolactone-Coated 3D Printed Tricalcium Phosphate Scaffolds for Bone Tissue Engineering: In Vitro Alendronate Release Behavior and Local Delivery Effect on In Vivo Osteogenesis

Autoren: Tarafder, Solaiman Bose, Susmita

Quelle: ACS Appl Mater Interfaces

Schlagwörter: Alendronate - administration & dosage, 0301 basic medicine, Polyesters, 02 engineering and technology, In Vitro Techniques, Rats, Sprague-Dawley, 03 medical and health sciences, Bone Density Conservation Agents - administration & dosage, Osteogenesis, Animals, Osteogenesis - drug effects, Bone Density Conservation Agents - pharmacology, Alendronate, Bone Density Conservation Agents, Tissue Engineering, Tissue Scaffolds, Polyesters - chemistry, 6. Clean water, Rats, Alendronate - pharmacology, Three-Dimensional, Printing, Three-Dimensional, Printing, Sprague-Dawley, 0210 nano-technology

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/24826838
https://pubs.acs.org/doi/pdf/10.1021/am501048n
http://pubs.acs.org/doi/full/10.1021/am501048n
https://pubs.acs.org/doi/10.1021/am501048n
http://pubs.acs.org/doi/abs/10.1021/am501048n
http://europepmc.org/articles/PMC4095936
https://pubag.nal.usda.gov/catalog/5276568

Prospective biomarker evaluation in patients with osteonecrosis of the jaw who received bisphosphonates

Autoren: Kyoung Ae Kong Jin Woo Kim In Ho Cha et al.

Weitere Verfasser: Kyoung Ae Kong Jin Woo Kim In Ho Cha et al.

Quelle: Bone. 57:201-205

Schlagwörter: Male, 0301 basic medicine, Histology, Physiology, Endocrinology, Diabetes and Metabolism, Diphosphonates/therapeutic use, Parathyroid hormone, 03 medical and health sciences, 0302 clinical medicine, 80 and over, Bisphosphonate, Humans, Bone Density Conservation Agents/administration & dosage, Aged, Aged, 80 and over, Jaw Diseases/drug therapy, Bone Density Conservation Agents, Diphosphonates, Bone Density Conservation Agents/therapeutic use, Osteonecrosis, CTx telopeptide, Middle Aged, Diphosphonates/administration & dosage, Osteonecrosis of jaw, Case-Control Studies, Osteonecrosis/drug therapy, Female, Biomarkers, Jaw Diseases

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/23954759
https://dspace.ewha.ac.kr/handle/2015.oak/224143
https://www.sciencedirect.com/science/article/pii/S8756328213003153
https://yonsei.pure.elsevier.com/en/publications/prospective-biomarker-evaluation-in-patients-with-osteonecrosis-o
https://pubmed.ncbi.nlm.nih.gov/23954759/
https://ir.ymlib.yonsei.ac.kr/handle/22282913/88741
http://www.sciencedirect.com/science/article/pii/S8756328213003153

Resorption Controls Bone Anabolism Driven by Parathyroid Hormone (PTH) Receptor Signaling in Osteocytes

Autoren: Matthew R. Allen Ana C. Ronda Yumie Rhee et al.

Weitere Verfasser: Matthew R. Allen Ana C. Ronda Yumie Rhee et al.

Quelle: Journal of Biological Chemistry. 288:29809-29820

Schlagwörter: 0301 basic medicine, Bone Resorption/metabolism, Gene Expression, Type 1/metabolism, Inbred C57BL, Transgenic, Mice, Absorptiometry, Photon, Alendronate/pharmacology, Bone Density, Osteogenesis, 0303 health sciences, Bone Resorption/prevention & control, Alendronate, Bone Density Conservation Agents, Reverse Transcriptase Polymerase Chain Reaction, Subcutaneous, Signal Transduction, Osteocyte, Osteocytes/metabolism, Photon, Immunohistochemistry, Osteogenesis/drug effects, Resorption, Parathyroid Hormone, Osteogenesis/genetics, Osteoclast, Intercellular Signaling Peptides and Proteins, Bone Remodeling, Wnt Signaling, Receptor, PTH Receptor, Bone Remodeling/genetics, Bone Resorption/genetics, Bone Modeling/Remodeling, Injections, Subcutaneous, Bone and Bones/metabolism, Mice, Transgenic, Gene Expression/drug effects, Glycoproteins/metabolism, Osteocytes, Bone and Bones, Injections, 03 medical and health sciences, Wnt Signaling Pathway/drug effects, Animals, Bone Density Conservation Agents/administration & dosage, Absorptiometry, Bone Density Conservation Agents/pharmacology, Wnt Signaling Pathway/genetics, Bone Resorption, Bone, Adaptor Proteins, Signal Transducing, Glycoproteins, Receptor, Parathyroid Hormone, Type 1, Bone and Bones/drug effects, Glycoproteins/genetics, Bone Density/drug effects, Mice, Inbred C57BL, Alendronate/administration & dosage, Bone Remodeling/drug effects, Osteocytes/drug effects, Sost/Sclerostin, Type 1/genetics

Zugangs-URL: http://www.jbc.org/content/288/41/29809.full.pdf
https://pubmed.ncbi.nlm.nih.gov/23963454
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3795280
https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/23963454/
https://europepmc.org/articles/PMC3795280
https://yonsei.pure.elsevier.com/en/publications/resorption-controls-bone-anabolism-driven-by-parathyroid-hormone-
https://pubmed.ncbi.nlm.nih.gov/23963454/
https://ir.ymlib.yonsei.ac.kr/handle/22282913/88642